Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. develops the investigational Aethlon Hemopurifier, an extracorporeal therapeutic device for oncology and other indications. Company news centers on clinical-stage development in solid tumors and infectious-disease applications, including safety, feasibility and dose-finding work for Hemopurifier treatments used alongside anti-PD-1 therapies such as pembrolizumab or nivolumab.
Recurring updates also address preclinical research on the device's GNA affinity resin, extracellular vesicle removal and inflammatory microRNAs, along with quarterly financial results, corporate updates and investor presentations. The company's disclosures describe a platform designed to selectively remove circulating pathogenic targets from biologic fluids.
Aethlon Medical (Nasdaq:AEMD) will release fiscal year-end results for the period ended March 31, 2026 at 4:15 p.m. ET on Wednesday, June 10, 2026. Management will host a conference call at 4:30 p.m. ET, followed by a Q&A session, with replay available through July 10, 2026.
Aethlon Medical (NASDAQ:AEMD) is monitoring the current Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda and remains prepared to discuss potential investigational use of its Hemopurifier with global health and regulatory authorities.
The Hemopurifier is an investigational device designed to remove enveloped viruses. In a 2014 emergency-use case in Germany, a critically ill Ebola (Zaire strain) patient received a single 6.5-hour treatment, with reported viral load decline from ~400,000 to ~1,000 copies/mL and undetectable virus five days later. The FDA previously granted an IDE supplement enabling a regulatory pathway for investigational Hemopurifier use in Ebola patients in the U.S. The device remains investigational, and Aethlon will continue to monitor the outbreak and respond to clinician inquiries.
Aethlon Medical (NASDAQ: AEMD) announced the independent DSMB completed a safety review of cohort 2 in its AEMD-2022-06 trial on March 24, 2026 and recommended advancing to cohort 3. No device-related SAEs or DLTs were reported and cohort 3 enrollment is open to receive three Hemopurifier treatments over one week.
The study (9–18 patients) evaluates safety, feasibility and dose-finding in patients with solid tumors receiving pembrolizumab or nivolumab, with primary endpoints focused on adverse events and safety labs.
Aethlon Medical (Nasdaq: AEMD) reported that an independent DSMB completed a safety review of cohort 2 in its AEMD-2022-06 oncology trial and recommended advancing to the third and final cohort. The DSMB found no safety concerns, with no device-related SAEs or DLTs reported to date.
Enrollment for Cohort 3 is open; participants will receive three Hemopurifier treatments over one week at three active clinical sites in Australia. Results will inform a future PMA study.
Aethlon Medical (Nasdaq: AEMD) has engaged Maxim Group LLC as exclusive financial advisor to evaluate strategic opportunities including partnerships, mergers, acquisitions or other transactions.
The company completed the second cohort of its Australian oncology trial and will submit safety data to the independent Data Safety Monitoring Board. No timeline or assurance of a transaction has been established.
Aethlon Medical (Nasdaq: AEMD) will present at the Emerging Growth Conference on February 25, 2026 from 12:30–1:00 PM ET. The live, interactive online presentation features a fireside chat with CEO and CFO Jim Frakes and a real-time Q&A for investors.
Registration is required to attend; an archived webcast will be posted on EmergingGrowth.com and the Emerging Growth YouTube channel after the event.
Aethlon Medical (Nasdaq: AEMD) reported fiscal Q3 results for the period ended December 31, 2025, while advancing clinical and R&D programs. Key facts: cash balance ~$7.0 million, Q3 operating loss of $2.06 million, and nine-month operating expenses down 26.9%. Cohort 2 enrollment in the Australian oncology trial is underway, EV Long COVID preclinical data published on bioRxiv, and an MTA with Stavro is evaluating Hemopurifier compatibility with a simplified blood treatment system.
Aethlon Medical (Nasdaq: AEMD) will release fiscal third quarter results for the period ended December 31, 2025 at 4:15 p.m. ET on February 12, 2026. Management will host a conference call at 4:30 p.m. ET the same day to review results and corporate developments.
Registered participants receive dial-in details; a replay will be available about one hour after the call through March 12, 2026 with conference ID 3024961.
Aethlon Medical (Nasdaq: AEMD) entered a private placement and warrant inducement to raise approximately $3.3 million in gross proceeds, expected to close on or about December 8, 2025. The company agreed to sell 595,897 shares of common stock (or pre-funded warrants) together with warrants to purchase an aggregate 1,042,820 shares at a combined effective offering price of $4.03 per share and accompanying warrant.
The investor agreed to exercise March 2025 warrants for 155,000 shares and September 2025 warrants for 55,555 shares at an amended exercise price of $4.03, and the company will issue 368,471 new unregistered warrants. All warrants will have a $4.03 exercise price and expire 5.5 years after shareholder approval. Maxim Group is sole placement agent.
Aethlon Medical (Nasdaq: AEMD) reported a preclinical ex vivo study (preprint posted 20 Nov 2025) showing the Hemopurifier's GNA affinity resin binds extracellular vesicles (EVs) in Long COVID plasma and decreases seven EV-associated microRNAs linked to inflammatory pathways.
The study found elevated large (100–500 nm) and small (40–200 nm) EVs in Long COVID samples versus recovered controls, increased mannose-positive large EVs, and correlated removal of small EVs by GNA resin. Pathway analysis suggested reduction of inflammatory signaling including JAK-STAT and increased tissue-repair signals. The paper is submitted for peer review.